vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and SHENANDOAH TELECOMMUNICATIONS CO (SHEN). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $91.6M, roughly 1.9× SHENANDOAH TELECOMMUNICATIONS CO). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -5.9%, a 7.5% gap on every dollar of revenue. On growth, SHENANDOAH TELECOMMUNICATIONS CO posted the faster year-over-year revenue change (7.2% vs 5.0%). Over the past eight quarters, SHENANDOAH TELECOMMUNICATIONS CO's revenue compounded faster (15.0% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Shenandoah Telecommunications Co is a U.S. regional telecom provider offering broadband internet, wireless voice/data services, digital cable TV, and fiber-optic solutions. It serves residential, small business and enterprise clients across Mid-Atlantic states, focusing on underserved rural and suburban markets in Virginia, West Virginia, Maryland and Pennsylvania.
PCRX vs SHEN — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $91.6M |
| Net Profit | $2.9M | $-5.4M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | -1.0% |
| Net Margin | 1.6% | -5.9% |
| Revenue YoY | 5.0% | 7.2% |
| Net Profit YoY | — | -95.8% |
| EPS (diluted) | $0.07 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $91.6M | ||
| Q3 25 | $179.5M | $89.8M | ||
| Q2 25 | $181.1M | $88.6M | ||
| Q1 25 | $168.9M | $87.9M | ||
| Q4 24 | $187.3M | $85.4M | ||
| Q3 24 | $168.6M | $87.6M | ||
| Q2 24 | $178.0M | $85.8M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-5.4M | ||
| Q3 25 | $5.4M | $-9.4M | ||
| Q2 25 | $-4.8M | $-9.0M | ||
| Q1 25 | $4.8M | $-9.1M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | $-143.5M | $-5.3M | ||
| Q2 24 | $18.9M | $-12.9M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -1.0% | ||
| Q3 25 | 3.5% | -8.0% | ||
| Q2 25 | 4.7% | -10.3% | ||
| Q1 25 | 1.2% | -6.9% | ||
| Q4 24 | 13.2% | -6.7% | ||
| Q3 24 | -82.8% | -4.8% | ||
| Q2 24 | 15.9% | -18.5% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -5.9% | ||
| Q3 25 | 3.0% | -10.5% | ||
| Q2 25 | -2.7% | -10.2% | ||
| Q1 25 | 2.8% | -10.4% | ||
| Q4 24 | — | -3.2% | ||
| Q3 24 | -85.1% | -6.0% | ||
| Q2 24 | 10.6% | -15.0% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.13 | ||
| Q3 25 | $0.12 | $-0.20 | ||
| Q2 25 | $-0.11 | $-0.19 | ||
| Q1 25 | $0.10 | $-0.19 | ||
| Q4 24 | $0.38 | $-0.34 | ||
| Q3 24 | $-3.11 | $-0.13 | ||
| Q2 24 | $0.39 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $27.3M |
| Total DebtLower is stronger | — | $642.4M |
| Stockholders' EquityBook value | $653.9M | $880.8M |
| Total Assets | $1.2B | $1.9B |
| Debt / EquityLower = less leverage | — | 0.73× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $27.3M | ||
| Q3 25 | $246.3M | $22.6M | ||
| Q2 25 | $445.9M | $29.1M | ||
| Q1 25 | $493.6M | $87.5M | ||
| Q4 24 | $484.6M | $46.3M | ||
| Q3 24 | $453.8M | $43.1M | ||
| Q2 24 | $404.2M | $43.8M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $642.4M | ||
| Q3 25 | $376.7M | $535.4M | ||
| Q2 25 | $580.5M | $513.1M | ||
| Q1 25 | $583.4M | $515.8M | ||
| Q4 24 | $585.3M | $418.0M | ||
| Q3 24 | — | $345.2M | ||
| Q2 24 | — | $297.4M |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $880.8M | ||
| Q3 25 | $727.2M | $892.7M | ||
| Q2 25 | $757.8M | $902.0M | ||
| Q1 25 | $798.5M | $910.5M | ||
| Q4 24 | $778.3M | $918.6M | ||
| Q3 24 | $749.6M | $925.4M | ||
| Q2 24 | $879.3M | $933.1M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.9B | ||
| Q3 25 | $1.3B | $1.9B | ||
| Q2 25 | $1.5B | $1.8B | ||
| Q1 25 | $1.6B | $1.8B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.6B | $1.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.73× | ||
| Q3 25 | 0.52× | 0.60× | ||
| Q2 25 | 0.77× | 0.57× | ||
| Q1 25 | 0.73× | 0.57× | ||
| Q4 24 | 0.75× | 0.46× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $28.8M |
| Free Cash FlowOCF − Capex | — | $-78.6M |
| FCF MarginFCF / Revenue | — | -85.8% |
| Capex IntensityCapex / Revenue | — | 117.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-257.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $28.8M | ||
| Q3 25 | $60.8M | $30.7M | ||
| Q2 25 | $12.0M | $20.9M | ||
| Q1 25 | $35.5M | $20.5M | ||
| Q4 24 | $33.1M | $20.6M | ||
| Q3 24 | $53.9M | $24.3M | ||
| Q2 24 | $53.2M | $2.5M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-78.6M | ||
| Q3 25 | $57.0M | $-51.4M | ||
| Q2 25 | $9.3M | $-65.3M | ||
| Q1 25 | $26.9M | $-62.7M | ||
| Q4 24 | $31.0M | $-72.0M | ||
| Q3 24 | $49.8M | $-51.3M | ||
| Q2 24 | $51.6M | $-78.3M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -85.8% | ||
| Q3 25 | 31.7% | -57.2% | ||
| Q2 25 | 5.1% | -73.7% | ||
| Q1 25 | 15.9% | -71.3% | ||
| Q4 24 | 16.6% | -84.3% | ||
| Q3 24 | 29.6% | -58.5% | ||
| Q2 24 | 29.0% | -91.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 117.2% | ||
| Q3 25 | 2.2% | 91.4% | ||
| Q2 25 | 1.5% | 97.3% | ||
| Q1 25 | 5.1% | 94.7% | ||
| Q4 24 | 1.1% | 108.4% | ||
| Q3 24 | 2.4% | 86.2% | ||
| Q2 24 | 0.9% | 94.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SHEN
| Residential And SMB Incumbent Broadband | $41.5M | 45% |
| Residential And SMB Glo Fiber Expansion Markets | $23.0M | 25% |
| Commercial Fiber | $20.3M | 22% |
| RLEC Other | $6.8M | 7% |
